xeloda
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $16.53 | $496.01 $496.01 (0%) | 🛒 Add to cart |
| 40 | $16.09 | $661.34 $643.61 (3%) | 🛒 Add to cart |
| 50 | $15.82
Best per pill | $826.68 $791.20 (4%) | 🛒 Add to cart |
Synonyms | |||
Xeloda, known generically as capecitabine, is an oral chemotherapeutic prodrug classified as an antimetabolite. It’s converted enzymatically to 5-fluorouracil (5-FU) directly within tumor tissue, allowing for targeted delivery with potentially reduced systemic toxicity compared to intravenous 5-FU. We initially saw it as just another fluoropyrimidine, but its unique activation pathway—mimicking the body’s own pyrimidine metabolism—gave it a distinct profile that changed outpatient chemotherapy for certain cancers.
## 1. Introduction: What is Xeloda? Its Role in Modern Medicine
Xeloda (capecitabine) is an oral chemotherapeutic agent, a prodrug that is selectively converted to its active form, 5-fluorouracil (5-FU), within tumor cells. It’s primarily used in the treatment of colorectal cancer, breast cancer, and gastric cancer. Its significance lies in its oral administration, which offers patients an alternative to continuous intravenous infusions, potentially improving quality of life and allowing for treatment in an outpatient setting. For many, it represented a shift towards more manageable, home-based cancer care regimens.
## 2. Key Components and Bioavailability of Xeloda
The active pharmaceutical ingredient is capecitabine. It’s formulated as biconvex, film-coated tablets in strengths of 150 mg and 500 mg. The brilliance—and complexity—of Xeloda’s design is its three-step enzymatic conversion. It’s absorbed as an intact molecule through the intestinal wall. Then, in the liver, the enzyme carboxylesterase converts it to 5’-deoxy-5-fluorocytidine (5’-DFCR). Cytidine deaminase, present in both the liver and tumor tissues, then converts that to 5’-deoxy-5-fluorouridine (5’-DFUR). The final, critical step occurs predominantly within tumor cells by the enzyme thymidine phosphorylase, which converts 5’-DFUR to the active drug, 5-fluorouracil. This tumor-selective activation is the cornerstone of its therapeutic rationale, aiming to deliver a higher concentration of the cytotoxic agent directly to the cancer site.
## 3. Mechanism of Action of Xeloda: Scientific Substantiation
Once converted to 5-FU inside the cancer cell, it exerts its cytotoxic effects through two main pathways. First, 5-FU is metabolized to fluorodeoxyuridine monophosphate (FdUMP), which inhibits thymidylate synthase (TS). TS is a key enzyme in the de novo synthesis of thymidine, a nucleotide essential for DNA replication and repair. By inhibiting TS, Xeloda causes a “thymineless death,” halting DNA synthesis and leading to cell apoptosis. Second, 5-FU can be incorporated into RNA in place of uridine, disrupting normal RNA processing and function. This dual mechanism creates a powerful anti-proliferative effect on rapidly dividing cancer cells. The selective activation by thymidine phosphorylase is key—this enzyme is often found in higher concentrations in many tumor types compared to healthy surrounding tissue.
## 4. Indications for Use: What is Xeloda Effective For?
Its use is firmly established in several oncology settings, always under the supervision of an oncologist.
Xeloda for Colorectal Cancer
It’s approved as adjuvant therapy for Dukes’ C colon cancer after complete resection of the primary tumor. It’s also used as first-line treatment for metastatic colorectal cancer, either as a single agent or in combination with other chemotherapies like oxaliplatin.
Xeloda for Breast Cancer
In metastatic breast cancer, it’s indicated after failure of prior taxane and anthracycline chemotherapy. It’s also used in combination with docetaxel after failure of prior anthracycline-based chemotherapy. Furthermore, it’s a cornerstone in the treatment of HER2-negative breast cancer, sometimes combined with targeted therapies.
Xeloda for Gastric Cancer
It is used in the first-line treatment of advanced gastric cancer, typically in combination with a platinum-based agent like cisplatin.
We’ve also seen off-label use in other malignancies where thymidine phosphorylase is overexpressed, such as pancreatic and biliary tract cancers, though the evidence base there is more limited.
## 5. Instructions for Use: Dosage and Course of Administration
Dosing is critically important and must be individualized. The standard regimen is administered in 3-week cycles: 1250 mg/m² twice daily (morning and evening) for 2 weeks, followed by a 1-week rest period. Doses are typically rounded to the nearest tablet strength for practicality.
| Indication | Recommended Dosage | Schedule | Administration |
|---|---|---|---|
| Adjuvant Colon Cancer | 1250 mg/m² | Twice daily for 2 weeks, then 1 week rest | Within 30 minutes after a meal |
| Metastatic Colorectal/Breast Cancer | 1250 mg/m² | Twice daily for 2 weeks, then 1 week rest | Within 30 minutes after a meal |
It must be taken with food—this isn’t a suggestion, it’s a necessity. Food slows gastric emptying and enhances the bioavailability of capecitabine, reducing the potential for severe gastrointestinal toxicity. I remember one of our first patients, a gentleman named Robert (62, stage III colon cancer), who didn’t grasp this. He took it on an empty stomach for two days and ended up with profound diarrhea and hand-foot syndrome that landed him in the hospital. We learned the hard way that patient education on administration is non-negotiable.
## 6. Contraindications and Drug Interactions with Xeloda
Absolute contraindications include known severe hypersensitivity to capecitabine, 5-fluorouracil, or any component of the formulation, and severe renal impairment (creatinine clearance below 30 mL/min). It’s also contraindicated in patients known to be deficient in dihydropyrimidine dehydrogenase (DPD), as this can lead to severe, life-threatening toxicity due to an inability to metabolize 5-FU.
Drug interactions are a major concern. Concomitant use with warfarin requires extreme caution; Xeloda can potentiate warfarin’s effects, leading to dangerous bleeding events and even death. We monitor INR weekly. Another critical interaction is with phenytoin; Xeloda can increase phenytoin levels, risking toxicity. Allopurinol may interfere with the activation of Xeloda and should generally be avoided. It’s not recommended during pregnancy or breastfeeding.
## 7. Clinical Studies and Evidence Base for Xeloda
The evidence is robust. The X-ACT trial was a pivotal phase III study in adjuvant colon cancer, showing that Xeloda was at least as effective as intravenous 5-FU/leucovorin (Mayo Clinic regimen) in terms of disease-free and overall survival, with a more favorable safety profile and convenience. In metastatic breast cancer, a large phase III trial demonstrated superior overall response rates and time to disease progression with Xeloda compared to comparator regimens after anthracycline and taxane failure. The MACH-GC meta-analysis in gastric cancer solidified its role, showing survival benefit with fluoropyrimidine/platinum combinations. The data is compelling, but it’s the translation of that data into real-world outcomes that truly matters.
## 8. Comparing Xeloda with Similar Products and Choosing a Quality Product
Xeloda’s primary competitor is intravenous 5-FU. The key differentiator is the route of administration. Xeloda offers convenience and avoids the need for central lines and infusion pumps, but it comes with its own unique toxicity profile, notably hand-foot syndrome, which can be dose-limiting. Compared to other oral fluoropyrimidines like S-1 (used more commonly in Asia), Xeloda has a broader global approval and a larger evidence base in Western populations. There is no “generic vs. brand” debate in the traditional sense for most clinicians, as capecitabine is the active molecule. The choice often boils down to the clinical scenario, patient preference, and the specific toxicity profile the treating oncologist is most comfortable managing.
## 9. Frequently Asked Questions (FAQ) about Xeloda
What is the most common side effect of Xeloda?
Hand-foot syndrome (palmar-plantar erythrodysesthesia) is extremely common. Patients experience numbness, tingling, pain, swelling, and redness on the palms and soles. Diarrhea, nausea, and fatigue are also very frequent.
How long can a patient stay on Xeloda treatment?
It depends on the indication and tolerance. In the adjuvant setting, it’s typically given for 6 months (8 cycles). In the metastatic setting, treatment continues until disease progression or unacceptable toxicity, which could be many months or even years in some responding patients.
Can Xeloda be combined with other cancer drugs?
Yes, frequently. Common combinations include Xeloda with oxaliplatin (XELOX or CAPOX regimen) for colorectal cancer, and with docetaxel or lapatinib for breast cancer. These combinations are often more effective but also carry a higher risk of side effects.
What should I do if I miss a dose of Xeloda?
Do not take the missed dose. Simply resume the usual schedule with the next planned dose. Do not double the dose to make up for a missed one.
## 10. Conclusion: Validity of Xeloda Use in Clinical Practice
Xeloda remains a validated, essential tool in the oncologist’s arsenal. Its risk-benefit profile is well-characterized. For appropriate patients with colorectal, breast, or gastric cancers, it provides a highly effective, convenient, and generally manageable treatment option. Its role is firmly established in both the adjuvant and metastatic settings. The key to its successful use lies in meticulous patient selection, diligent monitoring for and management of toxicities—especially hand-foot syndrome and diarrhea—and unwavering attention to dosing and administration guidelines.
I’ll never forget Sarah, a 48-year-old teacher with metastatic breast cancer that had spread to her liver. She’d failed anthracyclines and taxanes and was running out of options. We started her on single-agent Xeloda. The first cycle was rough—grade 2 hand-foot syndrome made it difficult for her to write on the chalkboard. We dose-reduced, used lots of urea-based cream and pyridoxine, which is a bit of a controversial move, some of my colleagues swear by it for HFS, others think it’s useless. I’m in the “might-help-won’t-hurt” camp. Anyway, we found her sweet spot at 1000 mg/m² twice daily. The skin issues became manageable. And her liver metastases? They stabilized. She didn’t have a dramatic shrinkage, but stable disease for her was a win. She was able to continue teaching part-time for another 18 months, which was everything to her. That’s the reality of this drug—it’s not always about cure, sometimes it’s about buying quality time, and doing it in a way that lets people stay in their own homes, not tethered to an infusion pump. We recently discharged her to hospice care after the disease finally progressed, but her husband sent a card thanking us for the “extra ordinary days” she had. That’s the longitudinal follow-up that the clinical trials don’t capture. It’s messy, it’s imperfect, but for the right patient, it’s a powerful option.